Last reviewed · How we verify
Colistin/Polymyxin B + Meropenem
This combination uses colistin/polymyxin B to disrupt bacterial cell membranes while meropenem inhibits cell wall synthesis, providing synergistic activity against multidrug-resistant gram-negative bacteria.
This combination uses colistin/polymyxin B to disrupt bacterial cell membranes while meropenem inhibits cell wall synthesis, providing synergistic activity against multidrug-resistant gram-negative bacteria. Used for Multidrug-resistant gram-negative bacterial infections, Carbapenem-resistant Enterobacteriaceae (CRE) infections, Pseudomonas aeruginosa infections resistant to standard therapy.
At a glance
| Generic name | Colistin/Polymyxin B + Meropenem |
|---|---|
| Sponsor | National University of Singapore |
| Drug class | Antibiotic combination (polymyxin + carbapenem) |
| Target | Bacterial cell membrane (polymyxins) and bacterial cell wall/penicillin-binding proteins (meropenem) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Colistin and polymyxin B are cationic cyclic peptides that bind to and disrupt the outer membrane of gram-negative bacteria, increasing permeability. Meropenem is a broad-spectrum carbapenem beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins. The combination is designed to overcome resistance mechanisms and provide enhanced bactericidal activity against difficult-to-treat infections, particularly those caused by carbapenem-resistant organisms.
Approved indications
- Multidrug-resistant gram-negative bacterial infections
- Carbapenem-resistant Enterobacteriaceae (CRE) infections
- Pseudomonas aeruginosa infections resistant to standard therapy
Common side effects
- Nephrotoxicity
- Neurotoxicity (polymyxin-related)
- Seizures
- Diarrhea
- Nausea
Key clinical trials
- Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (PHASE3)
- Optimising TREATment for Severe Gram-Negative Bacterial Infections (PHASE4)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Colistin/Polymyxin B + Meropenem CI brief — competitive landscape report
- Colistin/Polymyxin B + Meropenem updates RSS · CI watch RSS
- National University of Singapore portfolio CI